Meet the Team »  Medical Oncology »  Margaret A. Tempero, M.D.
Margaret A. Tempero, M.D.

Margaret A. Tempero, M.D.

Professor of Medicine
Department of Medicine
Division of Hematology/Oncology
Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research, UCSF

Contact Information

1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 353-9888
Fax: (415) 353-9931
Open Popup
  • Creighton University, Omaha, NE, B.S., 1969, Medical Technology
  • University of Nebraska Medical Center, Omaha, NE, M.S., 1974, Clinical Pathology
  • University of Nebraska Medical Center, Omaha, NE, M.D., 1977, Medicine
  • University of Nebraska Medical Center, Omaha, NE, Residency, 1980, Internal Medicine
  • University of Nebraska Medical Center, Omaha, NE, Fellowship, 1983, Oncology
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Medical Oncology
  • Department of Medicine, Division of Hematology Oncology
  • Member, UCSF Comprehensive Cancer Center
  • GI Oncology Program

Dr. Margaret Tempero is deputy director of the UCSF Helen Diller Family Comprehensive Cancer Center at Mount Zion. She is a pioneer in applying radioactively tagged antibodies for cancer therapy. She has led national research projects for gastrointestinal cancer, including pancreatic cancer.

She has held editorial positions on prestigious journals such as Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research and American Journal of Medicine. Tempero is a professor of hematology and oncology and is the Doris and Don Fisher Distinguished Professor in Clinical Research. Prior to joining UCSF Medical Center, she was deputy director of the Cancer Center at the University of Nebraska.

  1. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010 Oct; 8(9):972-1017.
  2. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-
  3. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12. 
  4. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20; 27(33):5660-9.
  5. Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5. 

X